for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catabasis Pharmaceuticals Inc

CATB.OQ

Latest Trade

2.95USD

Change

-0.13(-4.22%)

Volume

211,371

Today's Range

2.84

 - 

3.19

52 Week Range

1.25

 - 

8.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Perceptive Advisors Llc Reports A Stake Of 10.5% In Catabasis Pharmaceuticals As Of Jan. 28 - SEC Filing

Feb 8 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::PERCEPTIVE ADVISORS LLC REPORTS A STAKE OF 10.5% IN CATABASIS PHARMACEUTICALS AS OF JAN. 28 - SEC FILING.

Catabasis Pharmaceuticals Announces Acquisition Of Quellis Biosciences Inc.

Jan 29 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS ANNOUNCES ACQUISITION OF QUELLIS BIOSCIENCES INC..CATABASIS - PLANS TO USE PRIVATE PLACEMENT FINANCING PROCEEDS OF $110 MILLION TO COMPLETE IND-ENABLING STUDIES, PHASE 1A, PHASE 1B/2 TRIALS OF QLS-215.CATABASIS - ENTERED AGREEMENT FOR SALE OF SERIES X CONVERTIBLE PREFERRED STOCK IN PRIVATE PLACEMENT TO GROUP OF INSTITUTIONAL ACCREDITED INVESTORS.CATABASIS PHARMACEUTICALS - EXPECTS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION FOR QLS-215 IN FIRST HALF OF 2022.CATABASIS PHARMACEUTICALS - EXPECTS TO INITIATE A PHASE 1B/2 TRIAL IN PATIENTS AFFECTED BY HAE IN 2023 WITH INITIAL RESULTS ANTICIPATED BY END OF 2023.CATABASIS PHARMACEUTICALS - CATABASIS WILL CONTINUE TO BE LED BY ITS CURRENT MANAGEMENT TEAM.CATABASIS PHARMACEUTICALS - ACQUISITION OF QUELLIS WAS STRUCTURED AS A STOCK-FOR-STOCK TRANSACTION.

Catabasis Pharmaceuticals Says Board Approved Reduction In Company’S Workforce Of About 48%- SEC Filing

Dec 7 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS SAYS ON DECEMBER 4, BOARD APPROVED REDUCTION IN COMPANY’S WORKFORCE OF ABOUT 48%, TO A TOTAL OF 16 EMPLOYEES - SEC FILING.CATABASIS PHARMACEUTICALS - EXPECTS RESTRUCTURING TO RESULT IN ABOUT $2.8 MILLION IN REDUCED ANNUALIZED WORKFORCE EXPENSES ONCE PLAN FULLY IMPLEMENTED.CATABASIS PHARMACEUTICALS - CURRENTLY ESTIMATES TO INCUR CHARGES FOR ONE-TIME TERMINATION BENEFITS IN CONNECTION WITH RESTRUCTURING OF ABOUT $1 MILLION IN Q4.CATABASIS PHARMACEUTICALS SAYS EXPECTS TO COMPLETE THE REDUCTION IN WORKFORCE BY THE END OF THE FOURTH QUARTER OF 2020.

Catabasis Pharmaceuticals Reports Q3 2020 Results

Nov 12 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS TOTALED $52.9 MILLION AS OF SEPTEMBER 30, 2020.EXPECTS THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS FOR AT LEAST NEXT 12 MONTHS.

Catabasis Pharmaceuticals Announces Top-Line Results For The Phase 3 PolarisDMD Trial Of Edasalonexent In Duchenne Muscular Dystrophy

Oct 26 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FOR THE PHASE 3 POLARISDMD TRIAL OF EDASALONEXENT IN DUCHENNE MUSCULAR DYSTROPHY.CATABASIS PHARMACEUTICALS INC - POLARISDMD TRIAL DID NOT ACHIEVE PRIMARY OR SECONDARY ENDPOINTS.CATABASIS PHARMACEUTICALS - EDASALONEXENT WAS OBSERVED TO BE GENERALLY SAFE AND WELL-TOLERATED IN TRIAL.CATABASIS PHARMACEUTICALS - STOPPING ACTIVITIES RELATED TO DEVELOPMENT OF EDASALONEXENT INCLUDING ONGOING GALAXYDMD OPEN-LABEL EXTENSION TRIAL.CATABASIS - SECONDARY ENDPOINT TIMED FUNCTION TESTS ALSO DID NOT SHOW STATISTICALLY SIGNIFICANT IMPROVEMENTS FOR PHASE 3 POLARISDMD TRIAL.CATABASIS PHARMACEUTICALS - PLANS TO WORK WITH EXTERNAL ADVISORS TO EXPLORE AND EVALUATE STRATEGIC OPTIONS GOING FORWARD.CATABASIS PHARMACEUTICALS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND NO DOSE REDUCTIONS IN PHASE 3 TRIAL.

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.53

Aug 10 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q2 LOSS PER SHARE $0.53.

Catabasis Pharma Reports First Quarter Loss Per Share Of $0.50

May 12 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q1 LOSS PER SHARE $0.50.CATABASIS PHARMA - TOP-LINE RESULTS EXPECTED IN Q4 FROM FULLY ENROLLED EDASALONEXENT GLOBAL PHASE 3 POLARISDMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY.CATABASIS PHARMACEUTICALS - PHASE 3 POLARISDMD TRIAL IS INTENDED TO SUPPORT NDA FOR COMMERCIAL REGISTRATION OF EDASALONEXENT IN 2021.EXPECTS IT HAS SUFFICIENT CASH TO FUND OPERATIONS THROUGH A POTENTIAL NDA FILING AND INTO Q3 2021.AS OF MARCH 31, 2020, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $55.1 MILLION.

Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.55

March 10 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.55.CATABASIS PHARMACEUTICALS - AS OF DEC 31, 2019, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $36.2 MILLION.CATABASIS PHARMACEUTICALS - EXPECTS THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS THROUGH POTENTIAL NDA FILING AND INTO Q3 2021.EDASALONEXENT GLOBAL PHASE 3 POLARISDMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY TOP-LINE RESULTS EXPECTED IN Q4 2020.

Catabasis Pharmaceuticals Announces Pricing Of $23 Million Underwritten Public Offering

Jan 30 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS ANNOUNCES PRICING OF $23 MILLION UNDERWRITTEN PUBLIC OFFERING.CATABASIS PHARMACEUTICALS ANNOUNCES PRICING OF $23 MILLION UNDERWRITTEN PUBLIC OFFERING.CATABASIS PHARMACEUTICALS INC - PRICED OFFERING OF AGGREGATE OF 4.6 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.00 PER SHARE.

Catabasis Pharmaceuticals Announces Phase 3 Trial Enrolled Expected Patient Population

Dec 16 (Reuters) - Catabasis Pharmaceuticals Inc <CATB.O>::CATABASIS PHARMACEUTICALS ANNOUNCES PHASE 3 POLARISDMD TRIAL ENROLLED EXPECTED PATIENT POPULATION.CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS FROM PHASE 3 POLARISDMD TRIAL ARE EXPECTED IN Q4 OF 2020.CATABASIS PHARMACEUTICALS INC - PHASE 3 POLARISDMD TRIAL IS ANTICIPATED TO SUPPORT AN NDA FILING IN 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up